Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematology Development.
CD70 Molecular Characteristics & Key Mutations
CD70 (also known as CD27 ligand) is a member of the tumor necrosis factor superfamily (TNFSF7). It contains a TNF homology domain (THD; UniProt P32970) and forms a native trimeric structure critical for receptor binding. Two key mutations in the LPFS3 region have been documented: variant VAR_081988 leads to loss of protein expression, while VAR_081989 preserves expression but abolishes interaction with CD27. These mutations are essential for understanding target biology, designing functional assays, and validating therapeutic candidates.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD70 (CD27L) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD70 Products |
| Gene Delivery | CD70 Promise-ORF / Lentivirus Full-length ORF for stable cell lines; preserves native membrane topology. |
View CD70 Products |
| Benchmark Ab | Anti-CD70 (Sequence of Cusatuzumab) Recombinant positive control for binding and blocking assay validation. |
View CD70 Products |
| Validator | CD70 siRNA Set For knockdown verification and specificity controls. |
View CD70 Products |
| Related Target A | CD27 (TNFRSF7) Cognate receptor, critical for immune checkpoint pathway mapping. |
View CD27 Products |
| Related Target B | CD47 Synergistic target for bypassing macrophage-mediated evasion. |
View CD47 Products |
Additional Related Targets:
- CD47 – Synergistic target for macrophage checkpoint blockade; combined targeting can enhance anti-tumor immunity.
- TNFSF14 (LIGHT) – Homolog for counter-screening to confirm selectivity in binding assays.
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimeric Conformation Stability | HEK293 Expressed (Native Glycosylation), Sequence Verified |
| Cross-species (human/mouse/cyno) evaluation | Ortholog proteins available with >95% purity, Endotoxin controlled |
| ADC Internalization Assays | Full-length CD70 lentivirus enables stable cell lines with native conformation |
| TNFSF homolog off-target screening | High-purity homolog panel (CD40L, 4-1BBL, OX40L) for selectivity |
| Lack of positive controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False positives in binding screens | Validated siRNA included for specificity checks |
Live CD70 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD70 therapeutics is intensifying, with major players shifting focus from naked monoclonal antibodies to antibody-drug conjugates (ADCs) and allogeneic cell therapies. As first-generation therapies advance through the clinic, the next wave of R&D targets combinatorial regimens and next-generation ADC payloads to overcome solid tumor barriers and immune evasion. Key modalities include ADCs (Pfizer/Seagen, AbbVie, Ambrx), allogeneic CAR-T (Allogene Therapeutics), and mAbs/bispecifics (argenx, Janssen). Indications are expanding from hematologic malignancies (AML, lymphoma) to solid tumors such as renal cell carcinoma (RCC) and glioma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Pfizer/Seagen, AbbVie, Ambrx | RCC, SCLC, AML | Internalization Assay (Need high-purity ECD-Fc & stable cell lines) |
| Allogeneic CAR-T | Allogene Therapeutics | RCC, Hematologic Malignancies | Cytotoxicity Assays (Need full-length Lentivirus transduction) |
| mAb / Bispecific | argenx, Janssen | Lymphoma, Glioma, AML | ADCC/CDC & Cross-Reactivity (Need orthologs & benchmark Ab) |